Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAmélie FontaineAPAnthea Peters

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals that BTK inhibitors influence treatment choice in chronic lymphocytic leukemia, suggesting an emphasis on individualized care.

Key Points

  • Treatment selection between fixed-duration and continuous therapies shows similar usage across patients.
  • Fifty-one percent of patients selected targeted therapies like venetoclax-obinutuzumab as first-line treatments.
  • Observational analysis assessed treatment decisions in patients with chronic lymphocytic leukemia in Alberta, Canada.
  • Individualized factors such as age and genetic mutations drive therapy choice, supporting the need for further research.

Cite This Study

Fontaine et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d0https://doi.org/10.1182/blood-2025-4513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025
  2. 2An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025
  3. 3A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada2025
  4. 4Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  5. 5Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System2025 · 3 citations